company background image
524470 logo

Syncom Formulations (India) BSE:524470 Stock Report

Last Price

₹15.22

Market Cap

₹14.3b

7D

13.7%

1Y

105.1%

Updated

18 Jul, 2024

Data

Company Financials

Syncom Formulations (India) Limited

BSE:524470 Stock Report

Market Cap: ₹14.3b

524470 Stock Overview

Manufactures, markets, and sells pharmaceutical formulation products in India.

524470 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 524470 from our risk checks.

Syncom Formulations (India) Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syncom Formulations (India)
Historical stock prices
Current Share Price₹15.22
52 Week High₹18.65
52 Week Low₹7.15
Beta1.42
11 Month Change20.79%
3 Month Change20.89%
1 Year Change105.12%
33 Year Change78.01%
5 Year Change1,779.01%
Change since IPO912.74%

Recent News & Updates

Recent updates

Shareholder Returns

524470IN PharmaceuticalsIN Market
7D13.7%0.9%0.7%
1Y105.1%48.8%44.7%

Return vs Industry: 524470 exceeded the Indian Pharmaceuticals industry which returned 50.5% over the past year.

Return vs Market: 524470 exceeded the Indian Market which returned 44.7% over the past year.

Price Volatility

Is 524470's price volatile compared to industry and market?
524470 volatility
524470 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 524470 has not had significant price volatility in the past 3 months.

Volatility Over Time: 524470's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988555Vijay Bankdawww.syncomformulations.com

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.

Syncom Formulations (India) Limited Fundamentals Summary

How do Syncom Formulations (India)'s earnings and revenue compare to its market cap?
524470 fundamental statistics
Market cap₹14.31b
Earnings (TTM)₹253.14m
Revenue (TTM)₹2.63b

56.5x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524470 income statement (TTM)
Revenue₹2.63b
Cost of Revenue₹1.57b
Gross Profit₹1.07b
Other Expenses₹811.93m
Earnings₹253.14m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin40.44%
Net Profit Margin9.61%
Debt/Equity Ratio25.2%

How did 524470 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.